Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2010 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: December 6, 2006
Last updated: January 27, 2010
Last verified: January 2010

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Giving chemotherapy and bevacizumab before surgery or radiofrequency ablation may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well giving oxaliplatin and capecitabine together with bevacizumab followed by surgery and/or radiofrequency ablation works in treating patients with colorectal cancer that has spread to the liver and cannot be removed by surgery.

Condition Intervention Phase
Colorectal Cancer
Metastatic Cancer
Biological: bevacizumab
Drug: capecitabine
Drug: oxaliplatin
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Procedure: radiofrequency ablation
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy of Neoadjuvant XELOX/AVASTIN Therapy for Nonresectable Colorectal Liver Metastases With Secondary Hepatic Resection/Radiofrequency

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Conversion rate of nonresectable disease to resectable disease [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Disease-free and overall survival [ Designated as safety issue: No ]
  • Objective response rate [ Designated as safety issue: No ]
  • Duration of response [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: June 2007
Detailed Description:



  • Evaluate the conversion rate of nonresectable disease to resectable disease in patients with nonresectable liver metastases secondary to colorectal adenocarcinoma treated with neoadjuvant therapy comprising oxaliplatin, capecitabine, and bevacizumab followed by hepatic resection and/or radiofrequency ablation.
  • Evaluate progression-free survival of patients treated with this regimen.


  • Determine disease-free and overall survival of patients treated with this regimen.
  • Determine the toxicities of this regimen in these patients.


  • Neoadjuvant therapy: Patients receive oxaliplatin IV over 2 hours and bevacizumab IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for 4-6 courses in the absence of disease progression or unacceptable toxicity or until conversion to resectable disease.
  • Surgery and/or radiofrequency ablation (RFA): Patients undergo hepatic resection (with or without RFA) when tumor is deemed resectable. Patients with stable (< 8 lesions) and unresectable disease undergo laparoscopic or percutaneous RFA. RFA repeats once 4-6 weeks later.
  • Adjuvant therapy: Beginning 6-8 weeks after surgery and/or RFA, patients may receive adjuvant therapy comprising oxaliplatin, capecitabine, and bevacizumab, as in neoadjuvant therapy, for up to 4 courses.

After completion of study treatment, patients are followed every 4 months.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed colorectal adenocarcinoma metastatic to the liver

    • Unresectable liver metastases
  • Measurable disease
  • No evidence of extrahepatic metastases
  • No CNS metastases


  • ECOG performance status 0-1
  • Absolute neutrophil count > 1,500/mm^3
  • Platelet count > 100,000/mm^3
  • Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 45 mL/min
  • Urinary protein < 2+ by dipstick OR < 2 g by 24-hour urine collection
  • Bilirubin < 2 times ULN
  • SGOT and SGPT < 2 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 18 months after completion of study therapy
  • Able to take oral medications (e.g., no dysphagia or malabsorption symptoms)
  • No other prior malignancy unless in complete remission and off therapy for ≥ 5 years
  • No known allergy to the study drugs
  • No peripheral neuropathy > grade 1
  • No uncontrolled infection
  • No uncontrolled hypertension
  • No active bleeding or hemoptysis
  • No other serious concurrent illness within the past 12 months, including any of the following:

    • Nonstable coronary artery disease
    • Myocardial infarction
    • Transient ischemic attack
    • Cardiovascular accident


  • Recovered from prior therapy
  • At least 28 days since prior major surgery
  • Prior therapy for advanced disease allowed

    • No prior oxaliplatin-based therapy
  • Concurrent maintenance and palliative treatment during study chemotherapy allowed (e.g., nutritional or transfusional support or pain control)
  • No concurrent corticosteroids except when used under the following circumstances:

    • As oxaliplatin premedication
    • Anti-5-HT_3 as antiemetic
  • No concurrent cold cap or iced mouth rinses
  • No other concurrent chemotherapy
  • No placement of hepatic artery port for regional chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00408772

United States, California
University of California Davis Cancer Center
Sacramento, California, United States, 95817
Sponsors and Collaborators
University of California, Davis
Principal Investigator: Vijay Khatri, MD, FACS University of California, Davis
  More Information Identifier: NCT00408772     History of Changes
Other Study ID Numbers: CDR0000517440  UCDCC-131  UCDCC-200412546-3 
Study First Received: December 6, 2006
Last Updated: January 27, 2010
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
liver metastases
stage IV colon cancer
stage IV rectal cancer
adenocarcinoma of the colon
adenocarcinoma of the rectum
recurrent colon cancer
recurrent rectal cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action processed this record on December 09, 2016